DFB Pharmaceuticals, Inc.
Show jobs for this employer
9 articles about DFB Pharmaceuticals, Inc.
-
DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
9/18/2018
Soria investigational drug provides evidence of actinic keratosis (AK) lesion reduction without the local irritation of approved topical AK treatment products
-
DFB Pharma Launches NanOlogy To Take On Cancer At The Smallest Scale
9/12/2017
-
BioNeutral Group Signs Agreement With Specialty Pharmaceutical Company DFB Pharmaceuticals, Inc.
11/22/2010
-
DFB Pharmaceuticals, Inc. Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
4/23/2009
-
Herbert Slade, MD Joins DFB Pharmaceuticals, Inc. as Chief Medical Officer and Senior Vice President, Medical Affairs
4/12/2007
-
Braham Shroot, Ph.D., Chief Scientific Officer Of DFB Pharmaceuticals, Inc., Elected VP Of The Society For Investigative Dermatology
6/26/2006
-
Phyton Biotech, Inc., A DFB Pharmaceuticals, Inc. Affiliate, Signs Licensing Agreement With DiAthegen, LLC To Commercialize Growth Hormone Receptor Antagonist That Treats Acromegaly, Cancer, Diabetes
4/11/2006
-
DFB Pharmaceuticals, Inc. Promotes Duncan Aust, Ph.D. To Senior Vice President Of Research And Development, Branded Pharmaceuticals
3/28/2006
-
HEALTHPOINT Focused On Supply Availability, Service To Customers As IODOSORB(R) Gel, IODOFLEX(R) Pad Licensing Agreement Expires
12/23/2005